169 related articles for article (PubMed ID: 16253877)
1. Biology calls the targets: combining RNAi and disease biology.
van Es HH; Arts GJ
Drug Discov Today; 2005 Oct; 10(20):1385-91. PubMed ID: 16253877
[TBL] [Abstract][Full Text] [Related]
2. Can cell systems biology rescue drug discovery?
Butcher EC
Nat Rev Drug Discov; 2005 Jun; 4(6):461-7. PubMed ID: 15915152
[TBL] [Abstract][Full Text] [Related]
3. A rational approach to maximize success rate in target discovery.
Schneider M
Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
[TBL] [Abstract][Full Text] [Related]
4. Antisense and RNAi: powerful tools in drug target discovery and validation.
Lavery KS; King TH
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
[TBL] [Abstract][Full Text] [Related]
5. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.
Hardy LW; Peet NP
Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
8. Systems biology in drug discovery.
Butcher EC; Berg EL; Kunkel EJ
Nat Biotechnol; 2004 Oct; 22(10):1253-9. PubMed ID: 15470465
[TBL] [Abstract][Full Text] [Related]
9. How will RNAi facilitate drug development?
Bartz S; Jackson AL
Sci STKE; 2005 Aug; 2005(295):pe39. PubMed ID: 16077085
[TBL] [Abstract][Full Text] [Related]
10. RNA interference screening for the discovery of oncology targets.
Quon K; Kassner PD
Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
[TBL] [Abstract][Full Text] [Related]
11. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
Perrimon N; Friedman A; Mathey-Prevot B; Eggert US
Drug Discov Today; 2007 Jan; 12(1-2):28-33. PubMed ID: 17198970
[TBL] [Abstract][Full Text] [Related]
12. RNAi and high-content screening in target identification and validation.
Haney SA
IDrugs; 2005 Dec; 8(12):997-1001. PubMed ID: 16320133
[TBL] [Abstract][Full Text] [Related]
13. Prospects of RNA interference therapy for cancer.
Pai SI; Lin YY; Macaes B; Meneshian A; Hung CF; Wu TC
Gene Ther; 2006 Mar; 13(6):464-77. PubMed ID: 16341059
[TBL] [Abstract][Full Text] [Related]
14. Commercial potential of RNAi.
Jain KK
Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
[TBL] [Abstract][Full Text] [Related]
15. Short interfering RNA (siRNA): tool or therapeutic?
Cejka D; Losert D; Wacheck V
Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
[TBL] [Abstract][Full Text] [Related]
16. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
17. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
18. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
Singh SK; Hajeri PB
Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
[TBL] [Abstract][Full Text] [Related]
19. RNA interference in pain research.
Röhl T; Kurreck J
J Neurochem; 2006 Oct; 99(2):371-80. PubMed ID: 17029593
[TBL] [Abstract][Full Text] [Related]
20. RNA interference as potential therapy for neurodegenerative disease: applications to inclusion-body myositis?
Paulson H
Neurology; 2006 Jan; 66(2 Suppl 1):S114-7. PubMed ID: 16432138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
